Drug discovery process funnel diagram
Try Before you Buy Download Free Sample Product
Audience
Editable
of Time
Teams of designers have worked to develop and curate this collection of thousands of Drug Discovery Process Funnel Diagram. We have designs available for every occasion.
People who downloaded this PowerPoint presentation also viewed the following :
Drug discovery process funnel diagram with all 10 slides:
It is not very easy to organise thoughts and present ideas in a consistent way that tells and interesting story. However, with the use of the best available Drug Discovery Process Funnel Diagram, this becomes really easy to achieve.
FAQs for Drug discovery
So basically there are five stages: target identification (figuring out what to hit), lead compound discovery (finding molecules that actually work), preclinical testing with animals and lab stuff, then the three clinical trial phases in humans, and finally regulatory approval. Takes forever though - like 10-15 years typically. Pretty insane when you think about it. Each stage has specific goals you gotta hit before moving on. Oh and the failure rates are brutal, plus the requirements get way more strict as you go. If you're working on this stuff, just know what your phase needs upfront - it'll save you headaches later.
So drug researchers hunt for the molecular "switches" that go haywire in diseases - think proteins or genes that control the whole mess. GWAS studies are clutch for spotting genetic variations tied to diseases. They'll use genetic screening, proteomics, all that bioinformatics stuff to map pathways. Here's the catch though: just because you find something doesn't mean you can drug it. Small molecules need to actually stick to your target effectively. Honestly, I'd focus on well-studied pathways first instead of chasing some completely novel biology that might lead nowhere.
So HTS is basically this massive screening process where you test tons of compounds at once instead of going one by one like some kind of masochist. Think automated assembly line but for finding drug candidates. You set up these assays that can handle huge volumes - we're talking thousands or millions of compounds getting tested simultaneously. Pretty wild when you think about it. The tricky part is making sure your assays are solid enough to handle all that throughput without giving you a bunch of fake positives. Most people use it early on to whittle down those enormous compound libraries into something actually manageable.
So basically you take your target protein's 3D structure and design molecules that'll fit perfectly into its active site - like matching a key to a lock. First step is getting good structural data through X-ray crystallography or cryo-EM. Then computational modeling predicts how your potential drugs will actually bind. Way better than the old random screening approach, honestly. The cool part? You can design compounds with better specificity and way fewer side effects. Just make sure you've got solid structural data first - that's gonna make or break everything else you do.
So basically you're looking at informed consent first - people gotta really know what they're getting into, not just signing papers. Risk-benefit stuff is huge too. Animal testing? Ugh, that's honestly the worst part of this whole field but sometimes necessary. Once drugs actually make it to market, pricing becomes a nightmare - like how do you balance profits with people actually being able to afford life-saving meds? Get your ethics committee approval super early though, don't wait. And never rush safety stuff just because you're behind schedule.
So basically, preclinical is all the lab work - testing on cells and animals to see if your drug even works. Takes forever, like 3-6 years. Then clinical trials are the human testing part with three phases that get bigger each time. Here's the annoying thing though: just because it works in mice doesn't mean it'll work in people. Happens way more than you'd think. You can't skip to human trials until you've got solid preclinical data to show it won't kill anyone. It's honestly the most nerve-wracking jump in drug development.
Dude, drug discovery is getting wild right now. Companies are using AI to predict which compounds will actually work before they even make them in the lab. CRISPR's everywhere too - researchers can create way better disease models and find new targets. High-throughput screening is crazy fast now. They're even building digital twins of organs, which honestly still sounds like something out of a movie to me. But here's the thing - when you combine all these technologies, you're cutting discovery time from like 20 years down to maybe 5. If you're looking at this space, AI integration is where the real money is.
PK/PD are absolutely critical - I can't stress this enough. So PK is what your body does to the drug (absorption, distribution, metabolism, elimination) while PD is what the drug actually does to you. The thing is, you need both pieces working together or you're screwed. I've watched teams pour millions into compounds that looked amazing on paper but had terrible PK profiles. Your drug might be the most potent thing ever, but if it can't reach its target or gets metabolized too quickly, game over. Start testing this stuff early in discovery - way better to kill a bad compound now than after Phase II trials.
Dude, computational screening is a game changer. You can test millions of drug compounds on your computer before stepping foot in a lab. Molecular modeling shows you how drugs bind to proteins, simulations catch toxicity issues early, and you'll find good candidates way faster. It's honestly kind of wild how accurate the predictions are getting. The algorithms also optimize existing compounds and spot side effects before they become expensive problems. Oh, and it saves ridiculous amounts of money too. If you're not using computational methods in your pipeline yet, you're basically doing chemistry the hard way.
Honestly, most drugs fail because they're either unsafe or just don't work that well. You'll see toxicity issues pop up that somehow got missed in animal testing - which makes sense since humans aren't giant mice, right? Sometimes the manufacturing gets crazy expensive or regulators hate your approach. Business side can tank too if the market changes while you're still in trials. My advice? Set up checkpoints super early so you're not throwing millions at a Phase III disaster. Way better to kill a bad candidate fast.
So patient-centric research is basically flipping everything around - you start with what patients actually want instead of just developing whatever sounds cool in the lab. Companies are finally listening to real patient voices early on, using data from fitness trackers and patient groups to pick better drug targets. Honestly, it's about time after all those years of researchers just guessing what matters. Your trials end up measuring stuff patients care about (quality of life vs random blood markers), and you're solving actual problems. Oh, and definitely get patient advisory boards going early - plus those digital tools that track real experiences, not just clinical assumptions.
Ugh, the failure rate is brutal - we're talking 1 in 5,000 compounds actually making it to market. Clinical trials are like a death gauntlet where your drug can get axed at any stage for safety issues or just not working well enough. What's super frustrating is something that works amazingly in mice will completely bomb in humans because, shocker, we're not giant mice. The whole process takes 10-15 years and costs over a billion dollars per drug. My advice? Think about how you'll actually manufacture and test it from the very beginning instead of figuring that out later.
Dude, once you hit clinical trials, regulatory agencies own your timeline completely. They're gatekeepers for every phase - you need approval to start human testing, then again for each progression. FDA reviews take 6-12 months per submission if you're lucky (and honestly, when are we ever?). They'll throw curveballs too - requesting extra studies that weren't in your original plan. That can add literal years. My advice? Map out your regulatory strategy super early. Build in way more buffer time than you think you need for reviews.
Honestly, these partnerships are game-changers for drug discovery. Universities have all the brilliant researchers and cutting-edge science, but they're broke when it comes to actually getting stuff to market. Pharma companies? They've got deep pockets and know how to navigate the regulatory nightmare. So it works perfectly - academics find the cool compounds, then industry takes over for the expensive clinical trials. My old professor always said the best discoveries happen at these intersections. If you're serious about moving your research forward, definitely reach out to companies in your field.
Dude, AI is totally changing drug discovery right now. You can actually predict if compounds will work before burning through millions in lab testing. Machine learning finds drug targets that researchers would've completely missed otherwise. Clinical trials get way more efficient too - better design, early side effect detection, all that stuff. The data analysis alone is insane, like processing datasets no human team could touch. Honestly feels like we're living in sci-fi sometimes. If you're not already checking out AI partnerships for your pipeline, might want to jump on that soon before everyone else does.
-
Top Quality presentations that are easily editable.
-
Informative design.










